Advocacy intelligence hub — real-time data for patient organizations
Bristol-Myers Squibb — PHASE3
University of Modena and Reggio Emilia
Haisco Pharmaceutical Group Co., Ltd. — PHASE3
NINTEDANIB: FDA approved
NINTEDANIB: FDA approved
NINTEDANIB: FDA approved
Dragonboat Biopharmaceutical Company Limited — PHASE2
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance3
Jascayd
(NERANDOMILAST)Orphan drugBoehringer Ingelheim Pharmaceuticals, Inc.
12.1 Mechanism of Action Nerandomilast is an inhibitor of phosphodiesterase 4 (PDE4) with at least nine-fold preferential inhibition of the PDE4B isoe...
Ofev
(NINTEDANIB)Orphan drugBoehringer Ingelheim Pharmaceuticals, Inc.
12.1 Mechanism of Action Nintedanib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRT...
Pirfenidone
(PIRFENIDONE)Orphan drugAvKARE
Pyridone [EPC]
12.1 Mechanism of Action The mechanism of action of pirfenidone in the treatment of IPF has not been established.
Pirfenidone Capsule, 267 Mg
(PIRFENIDONE CAPSULE, 267 MG)Orphan drugstandardMacleods Pharmaceuticals Limited
Pyridone [EPC]
12.1 Mechanism of Action The mechanism of action of pirfenidone in the treatment of IPF has not been established.
Steven R Duncan, MD
University of Alabama at Birmingham
Robert M Tighe, MD, M.D
Duke University Health Systems
📍 DURHAM, NC
Marlies Wijsenbeek, MD PhD
Erasmus Medical Center
JianWu Dai, Ph.D
Chinese Academy of Sciences
Tanzira Zaman, MD, M.D
Cedars-Sinai
📍 WEST HOLLYWOOD, CA
Joel Moss, M.D.
National Heart, Lung, and Blood Institute (NHLBI)
📍 Bethesda, Maryland